NEW YORK (GenomeWeb) – Contract research organization Nanosyn today announced a multiyear research service agreement to provide its microfluidics screening and profiling capabilities to Forma Therapeutics.

Nanosyn will provide to Forma its lab-on-a-chip biology services, which comprises more than 500 mobility shift assays. Forma will have access to Nanosyn's screening and profiling services and fragment-based screening drug discovery platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.